Evidence map›Paper›PMID 36590744›Full record

ArticleJTCVS open2022

Trends and three-year outcomes of hepatitis C virus-viremic donor heart transplant for hepatitis C virus-seronegative recipients.

Jessica M Ruck, Alice L Zhou, Laura B Zeiser, Diane Alejo, Christine M Durand, Allan B Massie, Dorry L Segev, Errol L Bush, Ahmet Kilic

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTCVS open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jessica M RuckDivision of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Md.
Alice L ZhouDivision of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Md.
Laura B ZeiserDivision of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Md.
Diane AlejoDivision of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Md.
Christine M DurandDivision of Infection Disease, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md.
Allan B MassieDivision of Transplant Surgery, Department of Surgery, NYU Langone Health, New York, NY.
Dorry L SegevDivision of Transplant Surgery, Department of Surgery, NYU Langone Health, New York, NY.
Errol L BushDivision of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Md.
Ahmet KilicDivision of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Md.
Johns Hopkins University · USNYU Langone Health · US

Funding

Frailty and post-liver transplant delirium and cognitive impairment in older recipientsF32AG067642 · NIA · JOHNS HOPKINS UNIVERSITY · PI RUCK, JESSICA MOORE · 2021 to 2023
$258k
NIA NIH HHS F32 AG067642
6 · The paper itself

Abstract

Objective: Heart transplants (HTs) from hepatitis C virus (HCV)-viremic donors to HCV-seronegative recipients (HCV D+/R-) have good 6-month outcomes, but practice uptake and long-term outcomes overall and among candidates on mechanical circulatory support (MCS) have yet to be established. Methods: Using the Scientific Registry of Transplant Recipients, we identified US adult HCV-seronegative HT recipients (R-) from 2015 to 2021. We classified donors as HCV-seronegative (D-) or HCV-viremic (D+). We used multivariable regression to compare post-HT extracorporeal membranous oxygenation, dialysis, pacemaker, acute rejection, and risk of post-HT mortality between HCV D+/R- and HCV D-/R-. Models were adjusted for donor, recipient, and transplant characteristics and center HT volume. We performed subgroup analyses of recipients bridged with MCS. Results: From 2015 to 2021, the number of HCV D+/R- HT increased from 1 to 181 and the number of centers performing HCV D+/R- HT increased from 1 to 60. Compared with HCV D-/R- recipients, HCV D+/R- versus D-/R- recipients overall and among patients bridged with MCS had similar odds of post-HT extracorporeal membranous oxygenation, dialysis, pacemaker, and acute rejection; and mortality risk at 30 days, 1 year, and 3 years (all Conclusions: HCV D+/R- and D-/R- HT have similar outcomes at 3 years' posttransplant. These results underscore the opportunity provided by HCV D+/R- HT, including among the growing population bridged with MCS, and the potential benefit of further expanding use of HCV+ allografts.

Indexed as

aHR, adjusted hazard ratioaOR, adjusted odds ratioDAAs, direct-acting antiviralsDCD, donation after circulatory deathD–, HCV-seronegative donorD+, HCV-viremic donordonor poolECMO, extracorporeal membranous oxygenationHCV, hepatitis C virusheart transplanthepatitis CHT, heart transplantIABP, intra-aortic balloon pumpIQR, interquartile rangeLVAD, left ventricular assist deviceMCS, mechanical circulatory supportoutcomesR–, HCV-seronegative recipientSRTR, Scientific Registry of Transplant Recipients

Identifiers

PMID36590744
PMCPMC9801334
OpenAlexW4308342988

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.